Small-Molecule SRC Kinase Inhibitors for Selective Covalent Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective inhibitors of kinases such as c-SRC to address overexpression in certain cancers and resistance to Herceptin treatment, as existing inhibitors lack selectivity and are not fully explored for irreversible modes of action.
Innovation Solution
Development of irreversible small molecule inhibitors of SRC kinase, represented by compounds of Formula (I), which target specific kinase domains to inhibit c-SRC activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing kinase inhibitors are used, then kinase activity is inhibited, but selectivity is insufficient leading to off-target effects
Solution Approach 1:
The patent introduces a warhead group (E) with specific electrophilic properties that selectively reacts with the cysteine residue at the activation loop of SRC kinase. This local chemical modification at a specific functional site (cysteine thiol group) provides high selectivity for SRC while sparing other kinases that lack this specific cysteine environment, thereby resolving the selectivity contradiction.
Solution Approach 2:
The invention changes the mode of action from reversible competitive inhibition to irreversible covalent inhibition. By transforming the inhibitor from a reversible binder to an irreversible covalent modifier, the patent achieves enhanced selectivity and potency. The electrophilic warhead forms a permanent covalent bond with the target cysteine, eliminating off-target effects while maintaining therapeutic efficacy.
2Power
If reversible inhibitors are used, then kinase activity is inhibited, but potency is insufficient requiring higher doses
Solution Approach 1:
The patent transforms the inhibition mechanism from reversible to irreversible by introducing an electrophilic warhead that forms a covalent bond with the cysteine residue. This parameter change from reversible to irreversible inhibition dramatically increases potency, allowing effective inhibition at much lower doses compared to reversible inhibitors, thus resolving the potency-dose contradiction.
Solution Approach 2:
The inhibitor comprises a composite structure with distinct functional elements: a warhead group (E) for covalent binding, a linker (L) for structural connection, and a core scaffold with substituents (R1-R5) for target recognition and binding affinity. This composite design enables both high potency through irreversible binding and appropriate pharmacological properties, resolving the potency-dose issue.
3Reliability
If selective inhibitors are developed, then therapeutic efficacy is improved, but resistance mutations can still occur
Solution Approach 1:
The patent targets a highly conserved cysteine residue located in the activation loop of SRC kinase, a critical functional site essential for kinase activity. By targeting this conserved, functionally critical residue with an irreversible covalent bond, the inhibitor maintains high therapeutic efficacy while being less susceptible to resistance mutations, as mutations at this position would severely compromise kinase function and viability.
Solution Approach 2:
The irreversible covalent inhibition acts as a preliminary, permanent blockade of the kinase active site. By forming a stable covalent bond before resistance mutations can develop, the inhibitor prevents the kinase from functioning, thereby suppressing tumor growth and reducing the selective pressure that drives resistance mutation development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit SRC kinase activity, offering increased potency and selectivity, and can overcome resistance mutations, providing therapeutic benefits for various cancers including breast and colorectal cancers.
Implementation Method 1
E is an electrophile
Data Source
AI summary
Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof. Also disclosed herein are methods of using the compounds of Formula (I) in the treatment of certain diseases (e.g., cancer).